Niramai
AI-powered, non-invasive early breast cancer screening
Ready to see Niramai in action?
Book a personalized demo with our team.
Overview
Niramai’s AI-driven diagnostics platform enhances breast health screening by combining thermal imaging with proprietary machine learning algorithms to deliver accurate, automated assessments. The solution is portable, privacy-aware, and can be deployed in clinics, hospitals, and screening camps, helping detect cancer earlier even in younger women or dense breast tissue where mammography may underperform. Niramai’s flagship device SMILE-100 has received US FDA clearance, and the Thermalytix technology holds multiple patents and international approvals. The company also offers home screening services and partnership models for broader outreach.
Who It's For
Healthcare providers, Hospitals & clinics, Diagnostic centres, Public health programs, Women’s health advocates
Key Strengths
Early detection AINon-invasive & radiation-freePortable & cost-effectiveRegulatory cleared medical device
Primary Use Cases
AI-driven breast cancer screening
Portable screening for rural & remote areas
Clinic & hospital diagnostic support
Home-based screening services
Technical Specifications
Supported AI Models
Proprietary AIThermalytix Machine Learning
Deployment Methods
Cloud
Supported Languages
English
Security & Compliance
CE mark (Europe)
FDA clearance (US)
Company Information
Location
Bengaluru, India
Company Size
51-200 employees